1. Academic Validation
  2. Robust proteome profiling of cysteine-reactive fragments using label-free chemoproteomics

Robust proteome profiling of cysteine-reactive fragments using label-free chemoproteomics

  • Nat Commun. 2025 Jan 2;16(1):73. doi: 10.1038/s41467-024-55057-5.
George S Biggs # 1 2 3 Emma E Cawood # 1 4 Aini Vuorinen 1 2 3 William J McCarthy 2 Harry Wilders 1 5 Ioannis G Riziotis 1 6 Antonie J van der Zouwen 2 Jonathan Pettinger 1 Luke Nightingale 6 Peiling Chen 7 Andrew J Powell 1 David House 1 Simon J Boulton 4 J Mark Skehel 3 Katrin Rittinger 8 Jacob T Bush 9
Affiliations

Affiliations

  • 1 Crick-GSK Biomedical LinkLabs, GSK, Gunnels Wood Road, Stevenage, Hertfordshire, UK.
  • 2 Molecular Structure of Cell Signalling Laboratory, The Francis Crick Institute, London, UK.
  • 3 Proteomics Science Technology Platform, The Francis Crick Institute, London, UK.
  • 4 DSB Repair Metabolism Laboratory, The Francis Crick Institute, London, UK.
  • 5 University of Strathclyde, Pure and Applied Chemistry, Glasgow, UK.
  • 6 Software Engineering and AI, The Francis Crick Institute, London, UK.
  • 7 GSK Chemical Biology, GSK, Collegeville, PA, USA.
  • 8 Molecular Structure of Cell Signalling Laboratory, The Francis Crick Institute, London, UK. [email protected].
  • 9 Crick-GSK Biomedical LinkLabs, GSK, Gunnels Wood Road, Stevenage, Hertfordshire, UK. [email protected].
  • # Contributed equally.
Abstract

Identifying pharmacological probes for human proteins represents a key opportunity to accelerate the discovery of new therapeutics. High-content screening approaches to expand the ligandable proteome offer the potential to expedite the discovery of novel chemical probes to study protein function. Screening libraries of reactive fragments by chemoproteomics offers a compelling approach to ligand discovery, however, optimising sample throughput, proteomic depth, and data reproducibility remains a key challenge. We report a versatile, label-free quantification proteomics platform for competitive profiling of cysteine-reactive fragments against the native proteome. This high-throughput platform combines SP4 plate-based sample preparation with rapid chromatographic gradients. Data-independent acquisition performed on a Bruker timsTOF Pro 2 consistently identified ~23,000 cysteine sites per run, with a total of ~32,000 cysteine sites profiled in HEK293T and Jurkat lysate. Crucially, this depth in cysteinome coverage is met with high data completeness, enabling robust identification of liganded proteins. In this study, 80 reactive fragments were screened in two cell lines identifying >400 ligand-protein interactions. Hits were validated through concentration-response experiments and the platform was utilised for hit expansion and live cell experiments. This label-free platform represents a significant step forward in high-throughput proteomics to evaluate ligandability of cysteines across the human proteome.

Figures
Products